Cellectis SA (NASDAQ:CLLS)

2.36
Delayed Data
As of Sep 26
 -0.07 / -2.87%
Today’s Change
2.30
Today|||52-Week Range
13.74
-70.94%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$109.2M

Company Description

Cellectis SA operates as a clinical stage biotechnological company. The firm operates through the segments: Therapeutics and Plants. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and monogenic diseases. The Plants segment focuses on using Calyxt's proprietary PlantSpringTM technology platform to engineer plant metabolism to produce innovative, high-value, and sustainable materials and products for use in helping customers meet their sustainability targets and financial goals. The company was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Contact Information

Cellectis SA
8, rue de la Croix Jarry
Paris Ile-de-france 75013
P:(318) 169-1600
Investor Relations:

Employees

Shareholders

Other institutional11.89%
Mutual fund holders11.28%
Individual stakeholders--

Top Executives

André ChoulikaChief Executive Officer & Director
Bing C. WangChief Financial Officer
Philippe DuchateauChief Scientific Officer
Carrie BrownsteinChief Medical Officer
Stephan ReynierChief Regulatory & Compliance Officer